Neumora Therapeutics, Inc. (NMRA): Long-Term Debt

Annual figures by period end, from SEC filings.

$54.53M

As of 2025-12-31

$52.91M

As of 2026-06-30

Period ended	Long-Term Debt	Change YoY	Source filing
2025-12-31	$54.53M	n/a	2026-03-30, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Long-Term Debt	Change YoY
Neumora Therapeutics, Inc. (NMRA)	2025-12-31	$54.53M	n/a
Editas Medicine, Inc. (EDIT)	2024-12-31	$57.43M	n/a
Agenus Inc (AGEN)	2025-12-31	$44.66M	+34.6%
TScan Therapeutics, Inc. (TCRX)	2025-12-31	$32.53M	+1.4%
Adaptimmune Therapeutics PLC (ADAPY)	2024-12-31	$54.28M	n/a
X4 Pharmaceuticals, Inc (XFOR)	2025-12-31	$75.00M	0.0%
Alector, Inc. (ALEC)	2025-12-31	$10.00M	0.0%
Acumen Pharmaceuticals, Inc. (ABOS)	2025-12-31	$22.40M	-23.9%
Humacyte, Inc. (HUMA)	2025-12-31	$35.44M	n/a

Compare NMRA, EDIT, AGEN, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗